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Renal kallikrein-kinin system damage and salt sensitivity: In-
sights from experimental models. The importance of tubulo-
interstitial injury in the pathophysiology of human essential
hypertension, and particularly salt sensitivity, is increasingly
recognized. Since the renal kallikrein-kinin system (KKS) is
located in the tubulointerstitial region of the kidney it is rea-
sonable to expect that injury to this area, whatever the cause,
may impair KKS production and compromise its role in blood
pressure regulation.
In this review we discuss evidence of injury in the renal kal-
likrein-producing structures in three different experimental
models characterized by prominent tubulointerstitial lesions:
subtotal nephrectomy; inhibition of nitric oxide synthase; and
overload proteinuria. These three experimental models have
in common the development of important tubulointerstitial
damage and salt-sensitive hypertension expressed after the ini-
tial injury has ceased. In these three models, reduced KKS
activity may contribute to the establishment of a pathophysio-
logic state characterized by unopposed hyperactivity of the
renin-angiotensin system, resulting in salt retention.
The structural integrity of the tubulointerstitial areas
of the kidney plays an important role in the physiology
of sodium balance. Recent investigations suggest that tu-
bulointerstitial injury may be a critical feature in the de-
velopment of essential hypertension and, particularly, in
the development and maintenance of salt sensitivity [1].
Salt sensitivity is a term used to describe the hyperten-
sive state that is significantly modified by variations in
salt balance. Blood pressure is increased with a high-salt
diet and is reduced by a reduction in salt intake, asso-
ciated or not with furosemide administration [2, 3]. The
pressure natriuresis curve is shifted to the right since a
higher blood pressure is required to excrete an equiva-
lent amount of sodium. Salt sensitivity may be a signifi-
cant predictor of organ damage [3–5] and is such a com-
mon feature of essential hypertension, particularly in
elderly individuals, that current recommendations for the
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treatment of hypertension includes restriction of dietary
salt [6].
The role of tubulointerstitial injury in the development
of salt-sensitive hypertension is supported by the findings
of focal microvascular damage in the renal interstitium of
hypertensive patients [7, 8]. Identical intra-renal lesions
may be induced with the administration of angiotensin
II by subcutaneous minipumps in rats. This experimental
manipulation also results in the subsequent development
of hypertension if the rats are given a high-salt diet, while
the animals remain normotensive if salt intake is not in-
creased [9]. Similar findings were demonstrated in hyper-
tension induced by the infusion of phenylephrine, where
blood pressure was correlated with the degree of tubulo-
interstitial injury [10].
Subsequent observations in other experimental mod-
els are consistent with the postulate that tubulointer-
stitial damage and loss of peritubular capillary area are
common features in other types of salt-sensitive hyper-
tension [11]. In fact, the association of salt-sensitive hyper-
tension, tubulointerstitial immune cell infiltration, and
peritubular capillary loss has been found in several ex-
perimental conditions [12]
In general, the mechanisms proposed to explain salt
sensitivity in these models center on, first, the reduction
in peritubular capillary area which reduces the area avail-
able for the pressure-natriuresis mechanism to operate
efficiently, and second, the participation of humoral fac-
tors that favor sodium retention resulting from the infil-
tration of immunocompetent cells in tubulointerstitial
areas [1]. Local up-regulation of the renin-angiotensin
system, over-expression of angiotensin-converting-enzyme
(ACE) at sites of interstitial injury, and expression of
angiotensin II by infiltrating T cells, macrophages, and
resident tubular cells, have been documented [13, 14].
Over-expression of endothelin-1, a potent vasoconstric-
tor, has also been demonstrated.
However, less attention has been devoted to the role
of the vasodilator hormones in the phenomenon of salt
sensitivity. Previous studies of the hypokalemia model
showed a reduction in renal nitric oxide production,
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urinary prostaglandin excretion, and in the release of
renal medullipin [15]. Human studies have reported re-
duction of renal prostaglandins [16] and nitric oxide pro-
duction [17].
An important vasodilator system located in the re-
nal tubulointerstitial space is the kallikrein-kinin system
(KKS) [18]. This is a multienzymatic complex in which
the major components are an enzyme (renal kallikrein),
its substrates (renal high- and low-molecular weight ki-
ninogens), effector bioactive peptides (kinins, lys-brady-
kinin and bradykinin), the kinin-metabolizing enzymes
(ACE and neutral endopeptidase), the kinin receptors
(B1 and B2), and several activators/inhibitors of the sys-
tem [19]. This system behaves as a paracrine renal com-
plex in which the kinin peptides are formed and act
within the kidney mainly through the activation of B2
receptors, which appear to be constitutively expressed not
only in the kidney but also in many other cell types [18].
One of the key targets of kinin action is the collecting
duct that expresses B2 receptors on both basolateral and
luminal cell membranes [20]. After a delay period that
may be as short as three minutes, kinins cause a four-
to six-fold increase in the formation of prostaglandin E2
(PGE2) but only when added to the luminal surface of
canine cortical collecting duct cells in culture [21]. The
formation of PGE2 in the collecting duct fluid could me-
diate the natriuretic action of kinins, as PGE2 has been
reported to inhibit Na reabsorption in isolated rabbit
collecting ducts [22]. In contrast, kinins inhibit the argi-
nine vasopressin-stimulated water permeability and Na
reabsorption in isolated collecting ducts only when the
peptide is applied on the serosal side of the tubule [23, 24].
This effect is likely the result of inhibition of an arginine
vasopressin–dependent increase of cAMP, the major sec-
ond messenger produced after vasopressin V2 receptor
activation [25]. Furthermore, kinin B2 receptor blockade
enhances Cl and water absorption in the medullary
collecting ducts, a finding that supports a role of renal
kinins in the regulation of NaCl and water excretion [26].
B2 receptors have also been found in proximal straight
tubule, the distal straight tubule (thick ascending limb
of Henle), the connecting tubule, and afferent arterioles
[20, 27].
Kallikrein production is carried out in connecting tu-
bule cells, in the renal cortex [28], whereas its substrate,
kininogen, is synthesized downstream in collecting tu-
bules [29]. Anatomic vicinity of cells responsible for the
synthesis of both components makes possible kinin for-
mation and action at the luminal side of collecting tubule
cells, as well as in the peritubular space affecting renal
blood flow and electrolytes and water excretion. The site
of kallikrein synthesis is in close anatomical proximity
to the site of renin production since in the rat [30] and
in humans [31] both, the distal connecting tubule returns
to the vicinity of the vascular pole after its outward tra-
jectory to subcapsular areas.
Abundant evidence indicates that the KKS plays an
important role in blood pressure regulation, salt sensi-
tivity, water balance, electrolyte excretion, and growth-
modulating activity [32–34]. Indeed, essential hyperten-
sion has been characterized as a low urinary kallikrein
excretion state [35], and the subset of salt-sensitive pa-
tients show lower levels of urinary kallikrein compared
with those salt resistant [36]. Furthermore, normotensive
offspring of hypertensive parents and salt retainers have
shown low levels of urinary kallikrein excretion [35,
37–39]. The role of the KKS is emphasized by the fact
that when kallikrein is administered in pharmacologic
doses to hypertensive patients, their blood pressure is
reduced [40], and this effect is more pronounced in salt-
sensitive than salt-resistant individuals [41]. Experimen-
tal work has given comparable results; a rat strain inbred
for reduced urinary kallikrein excretion differs from nor-
mal-kallikrein Wistar rats not only in basal levels of
blood pressure, but also in the modifications of blood
pressure resulting from variations in sodium balance
[42, 43]. The protective role of the KKS against incre-
ments in blood pressure is further emphasized by the
finding of the early onset of salt-sensitive hypertension
in the kinin B2 receptor null mice [44]. On the other
hand, promotion of renal KKS activity by inhibition of
kinin catabolism, results in increased sodium excretion
and prevention of the development of hypertension [45].
Interesting pharmacologic studies [46] have shown that
long-term infusion of a subdepressor dose (700 ng/day,
intravenously) of purified rat urinary kallikrein attenu-
ates renal injury in salt-induced hypertension in Dahl
salt-sensitive rats in association with stimulation of the
KKS-prostaglandin and nitric oxide axes. Moreover, ad-
enovirus-mediated delivery of human tissue kallikrein
(KLK1) results not only in high-efficiency expression
and blood pressure reduction in the spontaneously hy-
pertensive rat (SHR) [47–49], but also protects against
renal injury and cardiac remodeling in the rat remnant
kidney model of chronic renal failure [50].
Further evidence for the responsibility of this vasodila-
tor system in blood pressure control is found in hyperten-
sive disorders of pregnancy, where low levels of urinary
kallikrein have been also described [51]. In summary,
accumulated evidence about the physiologic role of the
KKS in the control of blood pressure and salt excretion
modulation, as well as its location in the renal tubulo-
interstitium, makes it plausible that it may be involved
in blood pressure modifications induced by changes in
sodium balance.
METHODS
In this communication we present evidence of KKS
injury found in three experimental models of renal tubu-
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lointerstitial damage characterized by the subsequent
development of salt-sensitive hypertension. We have fo-
cused our attention in the structural appearance and tis-
sue expression of a pivotal component of the system, the
enzyme kallikrein, evaluated with immunohistochemical
techniques using sections of rat renal tissue previously
fixed in 4% formalin in phosphate-buffered saline (PBS),
and embedded in paraffin. Kallikrein detection was
achieved using a polyclonal antibody directed to rat uri-
nary kallikrein. As previously reported, the cross-reactiv-
ity of this antiserum assessed by dot-blot immunoassay
was strong for rK1, moderate for rK2 and rK7, and mini-
mal for rK9 [52]. Bound rabbit immunoglobulins were
detected using the labeled streptavidin-biotin system
(LSAB) peroxidase system. The extension and the in-
tensity of the labeled surface area were evaluated by using
a computerized imaging system previously described in
detail [53, 54]. Briefly, the degree of staining was calcu-
lated by the ratio of suitable binary threshold image and
the total field area, and integrating the intensity of the
staining in the specific areas, thus avoiding variability
induced by differences in the amount of total tissue ex-
amined. For each sample, a mean value was obtained
by analysis of 20 different fields (at 20 or 40, de-
pending of the amount of tissue evaluated) and excluding
glomeruli and blood vessels.
The nitric oxide inhibition model
Nitric oxide (NO), endothelium-derived relaxing fac-
tor [55, 56] has a crucial role in the regulation of vascular
tone and renal blood flow. Chronic inhibition of NO
synthesis, achieved by the oral administration of N-
nitro-l-arginine methyl ester (l-NAME) for 4 to 6 weeks,
induces a significant rise in blood pressure accompanied
by severe vascular glomerular damage and proteinuria
[57]. Renal injury and severity of hypertension are di-
rectly related to the level of salt intake [58].
Most of the vasodilatory effects of kinins appear to
be mediated by the release of NO from endothelial cells,
since endothelial denudation of large arteries abrogates
the vasorelaxant response to kinins [59]. B2 receptors
have been identified in the endothelium of large arteries
and smooth muscle layers in arterioles [60]. Within the
kidney, the vasodilatory response to bradykinin (B2 ago-
nist) is mediated by arachidonic acid metabolites and,
to a lesser extent, by NO [61–63].
Tubulointerstitial damage is likely to reduce kalli-
krein-producing tubular areas. Such damage has been
reported after long-term nitric oxide synthase inhibition
[64], an experimental manipulation that results in inter-
stitial inflammation, increased local activity of the renin-
angiotensin system, and salt sensitive hypertension [65]
We have examined the expression of renal kallikrein
in male rats sacrificed after receiving l-NAME for 21
and 28 days at a dose of 50 mg/kg while hydrated with
1% salt in the drinking water [abstract; Ardiles et al,
Book of the XX Chilean Congress of Nephrology, Hyper-
tension and Transplantation, 2002, pp 28). These animals
showed an important elevation of blood pressure after
the first week, whereas control animals receiving only
1% salt in the drinking water remained normotensive.
Kidneys of experimental animals showed important tu-
bulointerstitial damage with patchy areas of cellular in-
filtration and destruction of tubular structures. Immuno-
histochemistry demonstrated kallikrein-immunoreactive
connecting tubules in inflammatory areas and reduction
in the immunoexpression of the enzyme after the third
week (Fig. 1).
The model of 5/6 renal ablation
This model is characterized by progressive tubulo-
interstitial damage with inflammation and fibrosis [66]
and subsequent salt sensitivity [67], and it has been
shown to be suitable for testing the potential participa-
tion of KKS in the pathogenesis of hypertension. Tubulo-
interstitial damage is a recognized characteristic of this
model [68–70], and a reduction in urinary kallikrein lev-
els has been demonstrated [71, 72]. Figure 2 shows the
remnant kidney of 5/6 nephrectomized male Sprague-
Dawley rats after 4 weeks of surgery demonstrating se-
vere tubulointerstitial injury characterized by inflamma-
tory cellular infiltration, dilation, and atrophy of tubular
structures and a marked reduction in the tissue expres-
sion of kallikrein coincidental with an elevation in blood
pressure. Interestingly, when these animals were treated
with mycophenolate mofetil, attenuation of the tubuloin-
terstitial lesions, an increase in kallikrein tissue expres-
sion and normalization of blood pressure were observed
[54]. Experiments in which kallikrein gene is delivered
into rats with 5/6 reduction in renal mass show that this
experimental maneuver attenuates hypertension and
protects nephrectomized rats against renal injury and
cardiac remodeling [50]. Similar to kallikrein infusion
experiments, kallikrein gene delivery significantly de-
creased proteinuria and increased levels of urinary kinins
and cyclic guanosine monophosphate (GMP), while de-
creasing peripheral vascular resistance. Interestingly, kal-
likrein gene transfer also reduced glomerular sclerotic
lesions, tubular damage, and interstitial inflammation in
the kidney [50]. In summary, in the 5/6 renal ablation
model, as in other experimental models, tubulointersti-
tial damage in association with reduction in kallikrein
expression may predispose for salt sensitivity and its
functional recovery prevents the development of hyper-
tension.
The overload proteinuria model
This model has been used to study factors triggered
by non-immune interstitial inflammation that play a role
in the progression of renal diseases [73–83]. Proteinuria
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Fig. 1. (A ) Morphologic appearance of tubu-
lointerstitial damage in a representative case
of L-NAME treated animal. (B ) Quantitative
analysis of the immunohistochemical kallikrein
expression by computerized imaging system is
shown. *P 0.05 compared with controls. (C)
Immunoreactive kallikrein expression in a con-
trol and (D) l-NAME treated animal.
Fig. 2. (A ) Morphologic appearance of tubu-
lointerstitial damage in a representative case
of 5/6 nephrectomized (Nx) animal. (B) Quan-
titative analysis of the immunohistochemical
kallikrein expression by computarized im-
aging system *P 0.05 compared with sham).
Immunoreactive kallikrein expression in a (C )
sham and (D ) Nx animal.
is induced by the daily intraperitoneal injection of 1 to 2 g
of bovine serum albumin (BSA) to rats with or without
previous nephrectomy. This challenge induces massive
proteinuria, followed by substantial renal interstitial in-
flammation and tubular destruction. Previous studies with
this model have not focused on blood pressure changes
but recent investigations have shown that the administra-
tion of a high-salt diet, a week after the administration of
intraperitoneal BSA has stopped, induces salt-sensitive
hypertension in female Lewis rats [84]. In these studies,
the salt-sensitive hypertension is prevented if an immu-
nosuppressive drug, mycophenolate mofetil, is adminis-
tered during protein overload [84], suggesting that the
reduction in tubulointerstitial immune infiltration and
interstitial angiotensin II activity resulting from this ther-
apy, play a critical role in the pathogenesis of salt reten-
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Fig. 3. (A ) Morphologic appearence of tubu-
lointerstitial damage in a representative case
of bovine serum albumin (BSA) treated ani-
mal. (B) Quantitative analysis of the immuno-
histochemical kallikrein expression by compu-
terized imaging system. *P  0.05 compared
with control. Immunoreactive kallikrein ex-
pression in (C) control and (D) BSA treated
animals.
tion. We have performed similar experiments using
Sprague-Dawley that received 2 g of BSA intraperito-
neally for 2 weeks, while control rats received equivalent
volumes of vehicle. During the proteinuric stage, the ani-
mals developed hypertension after the third dose, which
remained significantly higher than the control during the
rest of the experimental period. The histologic examina-
tion of the kidneys (Fig. 3) disclosed severe tubulointer-
stitial damage, including focal inflammation, protein casts,
and tubular atrophy with tubular dilation. Immunohisto-
chemistry showed dilated kallikrein-containing tubules
(connecting segments), composed by flattened cells con-
siderably less stained than those in vehicle-treated ani-
mals [abstract; Ardiles et al, J Am Soc Nephrol 12:460A,
2001].
Recent unpublished experiments performed in our lab-
oratory have shown that stimulation of kallikrein produc-
tion with high-potassium diet before overload proteinuria
was induced, increasing renal kallikrein immunohisto-
chemical expression and urinary activity, reducing blood
pressure levels during the experiment. It appears likely
that extensive damage in kallikrein-producing structures
may disrupt the balance between vasocontrictors/salt-
retaining and vasodilators/salt-excreting factors, thus set-
ting the stage for salt retention and arterial hypertension.
CONCLUSION
Reduction in kallikrein expression accompanies the
development of tubulointerstitial injury in these three
experimental models of renal damage that are followed
by salt-sensitive hypertension. It is likely that the reduced
kallikrein immunohistochemical expression is associ-
ated with a reduction in the generation of kinin peptides,
leading to an imbalance that favors vasoconstrictive so-
dium–retaining humoral influences. Additional effects of
the KKS may lay a role in the antihypertensive effects
of the KKS since a reduced activity of the KKS may favor
the development of renal fibrosis and its pharmacologic
stimulation may preserve renal structural and functional
integrity. A therapeutic approach directed to protect the
KKS may therefore prevent or attenuate salt sensitivity
and progression of chronic renal disease.
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